Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease identified miR-338-3p targeting GPX3 and PTPRS.
Animals
Aorta
/ metabolism
Endothelial Cells
/ metabolism
Glutathione Peroxidase
/ genetics
HEK293 Cells
Humans
Hypertension
/ complications
Mice
MicroRNAs
/ genetics
Phosphoric Monoester Hydrolases
/ genetics
RNA, Messenger
Receptor-Like Protein Tyrosine Phosphatases, Class 2
/ genetics
Renal Insufficiency, Chronic
/ complications
Transcriptome
Vascular System Injuries
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
16
6
2022
medline:
30
6
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Hypertension is associated with vascular injury, which contributes to end-organ damage. MicroRNAs regulating mRNAs have been shown to play a role in vascular injury in hypertensive mice. We aimed to identify differentially expressed microRNAs and their mRNA targets in small arteries of hypertensive patients with/without chronic kidney disease (CKD) to shed light on the pathophysiological molecular mechanisms of vascular remodeling. Normotensive individuals and hypertensive patients with/without CKD were recruited ( n = 15-16 per group). Differentially expressed microRNAs and mRNAs were identified uniquely associated with hypertension (microRNAs: 10, mRNAs: 68) or CKD (microRNAs: 68, mRNAs: 395), and in both groups (microRNAs: 2, mRNAs: 32) with a P less than 0.05 and a fold change less than or greater than 1.3 in subcutaneous small arteries ( n = 14-15). One of the top three differentially expressed microRNAs, miR-338-3p that was down-regulated in CKD, presented the best correlation between RNA sequencing and reverse transcription-quantitative PCR (RT-qPCR, R2 = 0.328, P < 0.001). Profiling of human aortic vascular cells showed that miR-338-3p was mostly expressed in endothelial cells. Two of the selected top nine up-regulated miR-338-3p predicted targets, glutathione peroxidase 3 ( GPX3 ) and protein tyrosine phosphatase receptor type S ( PTPRS ), were validated with mimics by RT-qPCR in human aortic endothelial cells ( P < 0.05) and by a luciferase assay in HEK293T cells ( P < 0.05). A distinct transcriptomic profile was observed in gluteal subcutaneous small arteries of hypertensive patients with CKD. Down-regulated miR-338-3p could contribute to GPX3 and PTPRS up-regulation via the canonical microRNA targeting machinery in hypertensive patients with CKD. http://links.lww.com/HJH/C27.
Identifiants
pubmed: 35703228
doi: 10.1097/HJH.0000000000003160
pii: 00004872-202207000-00019
doi:
Substances chimiques
MIRN338 microRNA, human
0
MicroRNAs
0
RNA, Messenger
0
GPX3 protein, human
EC 1.11.1.-
Glutathione Peroxidase
EC 1.11.1.9
Phosphoric Monoester Hydrolases
EC 3.1.3.2
PTPRS protein, human
EC 3.1.3.48
Receptor-Like Protein Tyrosine Phosphatases, Class 2
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394-1405Subventions
Organisme : CIHR
ID : 123465
Pays : Canada
Organisme : CIHR
ID : 143348
Pays : Canada
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Schiffrin EL. Mechanisms of remodelling of small arteries, antihypertensive therapy and the immune system in hypertension. Clin Invest Med 2015; 38:E394–E402.
Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19:921–930.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522–531.
Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91:827–887.
Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci U S A 2015; 112:E1106–E1115.
Huo KG, Richer C, Berillo O, Mahjoub N, Fraulob-Aquino JC, Barhoumi T, et al. miR-431-5p knockdown protects against angiotensin ii-induced hypertension and vascular injury. Hypertension 2019; 73:1007–1017.
Berillo O, Huo KG, Fraulob-Aquino JC, Richer C, Briet M, Boutouyrie P, et al. Circulating let-7g-5p and miR-191-5p are independent predictors of chronic kidney disease in hypertensive patients. Am J Hypertens 2020; 33:505–513.
Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 2018; 34:506–525.
Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994; 23:83–91.
Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 4:e05005doi: 10.7554/eLife.05005.
doi: 10.7554/eLife.05005
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009; 25:1091–1093.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13:2498–2504.
Liu H, Sun Q, Wan C, Li L, Zhang L, Chen Z. MicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2. J Cell Physiol 2014; 229:1494–1502.
Jacovetti C, Abderrahmani A, Parnaud G, Jonas JC, Peyot ML, Cornu M, et al. MicroRNAs contribute to compensatory beta cell expansion during pregnancy and obesity. J Clin Invest 2012; 122:3541–3551.
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z, et al. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res 2014; 12:313–321.
Li P, Chen X, Su L, Li C, Zhi Q, Yu B, et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 2013; 8:e66782.
Sun J, Feng X, Gao S, Xiao Z. microRNA-338-3p functions as a tumor suppressor in human nonsmallcell lung carcinoma and targets Ras-related protein 14. Mol Med Rep 2015; 11:1400–1406.
Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ, Li GX. MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened. Jpn J Clin Oncol 2014; 44:13–21.
Zhang X, Wang C, Li H, Niu X, Liu X, Pei D, et al. miR-338-3p inhibits the invasion of renal cell carcinoma by downregulation of ALK5. Oncotarget 2017; 8:64106–64113.
Dai C, Chen X, Li J, Comish P, Kang R, Tang D. Transcription factors in ferroptotic cell death. Cancer Gene Ther 2020; 27:645–656.
Jin RC, Mahoney CE, Coleman Anderson L, Ottaviano F, Croce K, Leopold JA, et al. Glutathione peroxidase-3 deficiency promotes platelet-dependent thrombosis in vivo. Circulation 2011; 123:1963–1973.
Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004; 101:6062–6067.
Wu C, Macleod I, Su AI. BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res 2013; 41 (Database issue):D561–D565.
Baez-Duarte BG, Mendoza-Carrera F, Garcia-Zapien A, Flores-Martinez SE, Sanchez-Corona J, Zamora-Ginez I, et al. Multidisciplinary Research Group on Diabetes of the Instituto Mexicano del Seguro Social. Glutathione peroxidase 3 serum levels and GPX3 gene polymorphisms in subjects with metabolic syndrome. Arch Med Res 2014; 45:375–382.
Roxborough HE, Mercer C, McMaster D, Maxwell AP, Young IS. Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Nephron 1999; 81:278–283.
Nagai T, Anzai T, Kaneko H, Mano Y, Anzai A, Maekawa Y, et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 2011; 57:208–215.
Hao Y, Wu BG, Shi J, Chen YL, Sun ZQ, Zheng LQ, et al. Association of tag SNPs of GPx-3 with essential hypertension in rural Han Chinese in Fuxin, Liaoning, China. Chin Med J (Engl) 2011; 124:2113–2116.
Iwai N, Kajimoto K, Kokubo Y, Tomoike H. Extensive genetic analysis of 10 candidate genes for hypertension in Japanese. Hypertension 2006; 48:901–907.
Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke 2007; 38:41–49.
Voetsch B, Jin RC, Bierl C, Deus-Silva L, Camargo EC, Annichino-Bizacchi JM, et al. Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke 2008; 39:303–307.
Akhter MS, Biswas A, Rashid H, Devi L, Behari M, Saxena R. Screening of the GPX3 gene identifies the ‘T’ allele of the SNP -861A/T as a risk for ischemic stroke in young Asian Indians. J Stroke Cerebrovasc Dis 2014; 23:2060–2068.
Coles CH, Shen Y, Tenney AP, Siebold C, Sutton GC, Lu W, et al. Proteoglycan-specific molecular switch for RPTPsigma clustering and neuronal extension. Science 2011; 332:484–488.
Pulido R, Serra-Pages C, Tang M, Streuli M. The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc Natl Acad Sci U S A 1995; 92:11686–11690.
Ohtake Y, Saito A, Li S. Diverse functions of protein tyrosine phosphatase sigma in the nervous and immune systems. Exp Neurol 2018; 302:196–204.
Fry EJ, Chagnon MJ, Lopez-Vales R, Tremblay ML, David S. Corticospinal tract regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma deficient mice. Glia 2010; 58:423–433.
Shen Y, Tenney AP, Busch SA, Horn KP, Cuascut FX, Liu K, et al. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 2009; 326:592–596.
Lang BT, Cregg JM, DePaul MA, Tran AP, Xu K, Dyck SM, et al. Modulation of the proteoglycan receptor PTPsigma promotes recovery after spinal cord injury. Nature 2015; 518:404–408.
McLean J, Batt J, Doering LC, Rotin D, Bain JR. Enhanced rate of nerve regeneration and directional errors after sciatic nerve injury in receptor protein tyrosine phosphatase ς knock-out mice. J Neurosci 2002; 22:5481–5491.
Sapieha PS, Duplan L, Uetani N, Joly S, Tremblay ML, Kennedy TE, Di Polo A. Receptor protein tyrosine phosphatase sigma inhibits axon regrowth in the adult injured CNS. Mol Cell Neurosci 2005; 28:625–635.
Thompson KM, Uetani N, Manitt C, Elchebly M, Tremblay ML, Kennedy TE. Receptor protein tyrosine phosphatase sigma inhibits axonal regeneration and the rate of axon extension. Mol Cell Neurosci 2003; 23:681–692.
Doody KM, Stanford SM, Sacchetti C, Svensson MN, Coles CH, Mitakidis N, et al. Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy. Sci Transl Med 2015; 7:288ra76.
Bunin A, Sisirak V, Ghosh HS, Grajkowska LT, Hou ZE, Miron M, et al. Protein tyrosine phosphatase PTPRS is an inhibitory receptor on human and murine plasmacytoid dendritic cells. Immunity 2015; 43:277–288.
Ohtake Y, Kong W, Hussain R, Horiuchi M, Tremblay ML, Ganea D, et al. Protein tyrosine phosphatase sigma regulates autoimmune encephalomyelitis development. Brain Behav Immun 2017; 65:111–124.
Schiffrin E, Deng L, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin i-converting enzyme inhibitor comparison with effects of a beta-blocker. Am J Hypertens 1995; 8:229–236.
Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653–1659.
Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. JHypertens 2002; 20:71–78.
Kemp JR, Unal H, Desnoyer R, Yue H, Bhatnagar A, Karnik SS. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin–angiotensin system. J Mol Cell Cardiol 2014; 75:25–39.
Rana I, Velkoska E, Patel SK, Burrell LM, Charchar FJ. MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury. Am J Physiol Renal Physiol 2015; 309:F943–F954.
Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51:432–439.
Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 1):474–481.
Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478:103–109.
Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41:677–687.
Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36:312–318.
Schiffrin EL. Reactivity of small blood vessels in hypertension: relation with structural changes. State of the art lecture. Hypertension 1992; 19:II1–II9.
Schiffrin EL, Deng LY, Larochelle P. Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients. Clin Invest Med 1993; 16:177–186.
Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation--contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res 1987; 61:181–186.
Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ. Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993; 22:523–526.
Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28:785–790.
Briet M, Barhoumi T, Mian MO, Sierra C, Boutouyrie P, Davidman M, et al. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013; 2:e000128.
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.